Literature DB >> 8786119

Isolation of the human semaphorin III/F gene (SEMA3F) at chromosome 3p21, a region deleted in lung cancer.

R H Xiang1, C H Hensel, D K Garcia, H C Carlson, K Kok, M C Daly, K Kerbacher, A van den Berg, P Veldhuis, C H Buys, S L Naylor.   

Abstract

Small cell lung cancer (SCLC) has been correlated with a deletion in the short arm of chromosome 3, with the region 3p21 being lost from one homolog in almost all cases. Two SCLC cell lines have homozygous deletions in 3p21, and these deletions overlap with a fragment of chromosome 3 that has tumor suppression activity in vivo. We have isolated some cDNA clones from this region that are homologous to the genes constituting the semaphorin family. They represent a novel human semaphorin, termed sema III/F (HGMW-approved symbol SEMA3F), which is expressed as a 3.8-kb transcript in a variety of cell lines and tissues; it is detected as early as Embryonic Day 10 in mouse development. There is high expression in mammary gland, kidney, fetal brain, and lung and lower expression in heart and liver. Although there is reduced expression of this gene in several SCLC lines, no mutations were found. This semaphorin homolog has characteristics of a secreted member of the semaphorin III family, with 52% identity with mouse semaphorin E and 49% identity with chicken collapsin/semaphorin D.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8786119     DOI: 10.1006/geno.1996.0074

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  44 in total

Review 1.  Semaphorins in angiogenesis and tumor progression.

Authors:  Gera Neufeld; Adi D Sabag; Noa Rabinovicz; Ofra Kessler
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

2.  Semaphorin SEMA3F localization in malignant human lung and cell lines: A suggested role in cell adhesion and cell migration.

Authors:  E Brambilla; B Constantin; H Drabkin; J Roche
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

3.  Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesis.

Authors:  John R Basile; Rogerio M Castilho; Vanessa P Williams; J Silvio Gutkind
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-05       Impact factor: 11.205

4.  Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cells.

Authors:  Sophie Kusy; Patrick Nasarre; Daniel Chan; Vincent Potiron; David Meyronet; Robert M Gemmill; Bruno Constantin; Harry A Drabkin; Joëlle Roche
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

Review 5.  Navigating breast cancer: axon guidance molecules as breast cancer tumor suppressors and oncogenes.

Authors:  Gwyndolen C Harburg; Lindsay Hinck
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-08-05       Impact factor: 2.673

6.  Inhibitory effects of Semaphorin 3F as an alternative candidate to anti-VEGF monoclonal antibody on angiogenesis.

Authors:  Gamze Tan
Journal:  In Vitro Cell Dev Biol Anim       Date:  2019-08-16       Impact factor: 2.416

7.  Gleevec/imatinib, an ABL2 kinase inhibitor, protects tumor and endothelial cells from semaphorin-induced cytoskeleton collapse and loss of cell motility.

Authors:  Vera Procaccia; Hironao Nakayama; Akio Shimizu; Michael Klagsbrun
Journal:  Biochem Biophys Res Commun       Date:  2014-04-20       Impact factor: 3.575

8.  ZEB-1, a repressor of the semaphorin 3F tumor suppressor gene in lung cancer cells.

Authors:  Jonathan Clarhaut; Robert M Gemmill; Vincent A Potiron; Slimane Ait-Si-Ali; Jean Imbert; Harry A Drabkin; Joëlle Roche
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

Review 9.  The role of semaphorins and their receptors in vascular development and cancer.

Authors:  Chenghua Gu; Enrico Giraudo
Journal:  Exp Cell Res       Date:  2013-02-17       Impact factor: 3.905

Review 10.  Potential therapeutic strategies for lymphatic metastasis.

Authors:  Bernadette M M Zwaans; Diane R Bielenberg
Journal:  Microvasc Res       Date:  2007-09-19       Impact factor: 3.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.